BTIG is cutting its price target on Valeant Pharma (NYSE: VRX) from $210 down to $175, but maintaining a Buy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Valeant Pharmaceuticals' (VRX) Buy Rating Affirmed at TD SecuritiesOctober 26, 2015 3:33 PM Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Valeant Pharmaceuticals International, Inc. InvestorsOctober 26, 2015 2:13 PM Martin Shkreli Exits Long Valeant Pharma (VRX)/short Allergan (AGN) Trade for Loss of 3%October 26, 2015 1:57 PM Valeant Pharma (VRX) Halts the Bloodletting Following Conference CallOctober 26, 2015 1:03 PM Fund Should Consider Gaining Exposure to Valeant 'Collateral Damage' Stocks - Citron's LeftOctober 26, 2015 12:19 PM